Newsroom > Articles


January 20, 2021, Paris, France

The iHealth Group of Brazil and Medexprim partner to accelerate international clinical research in Brazil, and to boost the identification and the recruitment of patients into clinical trials.

The iHealth Group, formed by a team with expert knowledge of the Brazilian health system, delivers products that contribute to the evolution of e-health in Brazil. The iHealth group maintains a local hospitals network equipped with partner Clinerion’s technology, allowing for the extraction of clinical data.

Medexprim is an accelerator of hospital clinical research and a tool for leveraging data from its partner hospitals. The French startup is the European expert in generating regulatory- grade datasets of aggregated images and clinical data, in compliance with ethics and regulations. Through a network of European academic hospitals and global data partners, Medexprim helps biopharmaceutical companies access specific datasets and design more successful, cost effective and faster clinical trials.

This strategic partnership opens up Brazil for Medexprim’s data and evidence services for biopharma: “The addition of iHealth Group to the Medexprim network is an important milestone in our expansion and marks our entry into South America,” says Romain Cazavan, CEO of Medexprim, “It brings a potential access to 15 Brazilian hospitals in 2021”. With Medexprim’s solution, iHealth Group gains access to academic and pharmaceutical research projects, as well as the ability to respond to more complex data requests for clinical research projects. Local partner hospitals will benefit from new tools to stimulate their own research, participate in external scientific collaborations, and receive R&D related fundings and compensations.

About iHealth Group

The iHealth Group has a multidisciplinary team focused on serving the health informatics industry. Our team has extensive experience in this topic, leading the process of computerization of more than 30 Brazilian hospitals. Digital health transformation will enable us to improve communication with our patients, optimize our queues, improve the safety of our processes, expand our planning capacity, reduce costs, eliminate waste and, especially, do evidence-based management. However, we must understand that it is not the technology, but strategic management that will guide us correctly to the computerization of our health processes. IT cannot be a strategic goal, but an instrument to achieve a goal.


About Medexprim

Medexprim, founded in 2015 and based in Toulouse, Paris, London and Boston, is the European leader in imaging data and clinical data extraction to accelerate clinical research. With R-WiDE Strategy (From Real-World Imaging Data to Evidence), Medexprim wants to address clinical trial efficiency for Biopharma by delivering synthetic patients thanks to its network of European Hospitals and its best-in-class international partners.


Medexprim Press contact

Anne-Sophie Labeta

3 questions to Coralie Carron

As a Ph.D. holder in Cellular and Molecular Biology, Coralie Carron assumes the pivotal…

CIAN: Cohort Imaging Analytics Network

Medexprim enables the aggregation, curation and enrichment of multicentric and multimodal cohorts of Real-World…

💡Scientific Insights – Read Samuel Boucher’s Take on the future…

Medexprim’s researchers and engineers contribute daily to the advancement of scientific research. Our researchers…

PR – Medexprim partners with Avicenna.AI to help validate their…

Medexprim, the European leader in multimodal Real-World datasets for clinical research, is pleased to…